PharmaEssentia

6446.TW

15.57 USD

-0.04

-0.26%

Overview

Last close

15.57 usd

Market cap

5.31B usd

52 week high

23.57 usd

52 week low

13.51 usd

Target price

20.45 usd

Valuation

P/E

37.7315

Forward P/E

N/A

Price/Sales

11.8133

Price/Book Value

5.4859

Enterprise Value

4.54B usd

EV/Revenue

10.3142

EV/EBITDA

33.6407

Key financials

Revenue TTM

440.25M usd

Gross Profit TTM

392.57M usd

EBITDA TTM

128.47M usd

Earnings per Share

0.41 usd

Dividend

0.03 usd

Total assets

867.04M usd

Net debt

-583.77M usd

About

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.